GLEN MILLS, Pa.--(BUSINESS WIRE)--Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency, high-resolution ultrasound imaging, today announced that it had gained additional FDA marketing clearance for its EPISCAN high-resolution ultrasound imaging system. The expanded clearance, which has the FDA reference number K062571, is summarized by the indications of use statement below and is in addition to the FDA clearance previously obtained under reference number K990238. This clearance will enable Longport to directly market for specific clinical applications as described below.
